JP2020111571A5 - - Google Patents

Download PDF

Info

Publication number
JP2020111571A5
JP2020111571A5 JP2020002515A JP2020002515A JP2020111571A5 JP 2020111571 A5 JP2020111571 A5 JP 2020111571A5 JP 2020002515 A JP2020002515 A JP 2020002515A JP 2020002515 A JP2020002515 A JP 2020002515A JP 2020111571 A5 JP2020111571 A5 JP 2020111571A5
Authority
JP
Japan
Prior art keywords
substituent group
halogen
substituted
group
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020002515A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020111571A (ja
JP7068743B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020111571A publication Critical patent/JP2020111571A/ja
Publication of JP2020111571A5 publication Critical patent/JP2020111571A5/ja
Application granted granted Critical
Publication of JP7068743B2 publication Critical patent/JP7068743B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020002515A 2019-01-11 2020-01-10 Mgat2阻害活性を有する縮合環誘導体を含有する医薬組成物 Active JP7068743B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019003070 2019-01-11
JP2019003070 2019-01-11

Publications (3)

Publication Number Publication Date
JP2020111571A JP2020111571A (ja) 2020-07-27
JP2020111571A5 true JP2020111571A5 (fr) 2022-03-04
JP7068743B2 JP7068743B2 (ja) 2022-05-17

Family

ID=71666534

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020002515A Active JP7068743B2 (ja) 2019-01-11 2020-01-10 Mgat2阻害活性を有する縮合環誘導体を含有する医薬組成物

Country Status (1)

Country Link
JP (1) JP7068743B2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114685502A (zh) * 2020-12-25 2022-07-01 由理生物医药(上海)有限公司 作为kras-g12c抑制剂的螺环类化合物
AU2022344074A1 (en) * 2021-09-08 2024-02-29 Shionogi & Co., Ltd. Medicine for prevention and treatment of diseases linked to anti-obesity activity
WO2023154766A1 (fr) 2022-02-09 2023-08-17 Quanta Therapeutics, Inc. Modulateurs de kras et leurs utilisations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014009165A (ja) 2012-06-27 2014-01-20 Dainippon Sumitomo Pharma Co Ltd 二環性ピリミジン化合物
JPWO2014133134A1 (ja) 2013-02-28 2017-02-02 味の素株式会社 新規テトラヒドロピリドピリミジノン誘導体
SG11201607392SA (en) 2014-03-07 2016-10-28 Bristol Myers Squibb Co Dihydropyridinone mgat2 inhibitors for use in the treatment of metabolic disorders
JP6522646B2 (ja) 2014-03-27 2019-05-29 ヤンセン ファーマシューティカ エヌ.ベー. ROS1阻害剤としての置換4,5,6,7−テトラヒドロ−ピラゾロ[1,5−α]ピラジン誘導体および5,6,7,8−テトラヒドロ−4H−ピラゾロ[1,5−α][1,4]ジアゼピン誘導体
WO2017069224A1 (fr) 2015-10-22 2017-04-27 塩野義製薬株式会社 Dérivé spiro hétérocyclique présentant une activité inhibitrice de mgat2
TWI782056B (zh) 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有mgat2抑制活性的縮合環衍生物

Similar Documents

Publication Publication Date Title
JP2020111571A5 (fr)
JP2019094345A5 (fr)
JP2019034943A5 (fr)
JP2019517487A5 (fr)
JP2011509309A5 (fr)
JP2016518437A5 (fr)
JP2020533352A5 (fr)
JP2013545791A5 (fr)
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
RU2008119994A (ru) Ингибиторы калиевых каналов
RU2007116987A (ru) Новые соединения
JPWO2019213318A5 (fr)
JP2017505293A5 (fr)
JP2018135343A5 (fr)
JPWO2022216971A5 (fr)
JP2016500063A5 (fr)
JPWO2019013311A5 (fr)
JP2019520344A5 (fr)
JPWO2019195124A5 (fr)
JP2013542267A5 (fr)
JP2010527985A5 (fr)
JP2020534266A5 (fr)
JPWO2020123827A5 (fr)
JP2005526773A5 (fr)
JP2019516726A5 (fr)